All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1600+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

GSK's Jemperli (PD-1 inhibitor) lands EMA approval as first-line treatment for advanced endometrial cancer, combined with chemo
Monoclonal antibody, endometrial cancer - Read more

Formycon, Klinge Biopharma’s aflibercept (Eylea biosimilar, Regeneron/Bayer) scores EMA approval for wet macular degeneration and other retinal diseases
Fusion protein, age-related neovascular macular degeneration, diabetic macular edema, retinal vein occlusion, biosimilar - Read more

THE GOOD
Business Development

InnoCare Pharma, KeyMed Biosciences out-licenses ICP-B02 (targeting CD20, CD3) rights to Prolium Biosciences in deal worth up to $520M; non-oncology indications globally, oncology indications ex-Asia
Bispecific antibody, cancer, solid tumor - Read more

THE GOOD
Clinical Trials

YolTech's YOLT-204 in vivo gene editing asset enters the clinical with Ph1 trial for beta-thalassemia
Gene editing, beta-thalassemia - Read more

THE GOOD
Fundraises

Kane Biotech $1.275M private placement
Microbial biofilm removal, sanitation, infectious disease - Read more

PRESENTED BY YOU?
Get the attention of 1600+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

⬇️ More Good News ⬇️

THE GOOD
IPOs

Odyssey Therapeutics seeks $100M IPO to advance autoimmune therapies, with Phase 2 trials planned ulcerative colitis
Small molecule, ulcerative colitis - Read more

Sionna Therapeutics files $100M IPO, developing cystic fibrosis therapies that target CFTR’s nucleotide-binding domain 1
Small molecule, cystric fibrosis - Read more

THE GOOD
Marketing

Sumitomo Pharma and Janssen partner to co-promote schizophrenia treatments Xeplion and Xeplion TRI in Japan from 2025
Small molecule, schizophrenia, co-marketing - Read more

THE GOOD
Mergers & Acquisitions

Taro Pharmaceuticals (Sun Pharma subsidiary) to acquire Canadian biotech Antibe Therapeutics
Small molecule, pain, inflammatory bowel disease - Read more

THE GOOD
Partnerships

Junshi Biosciences, LEO Pharma partner to distribute cancer drug toripalimab (targeting PD-1) across 32 European countries
Monoclonal antibody, cancer, distribution partnership - Read more

THE GOOD
Politics & Policy

Outgoing President Biden preemptively pardons Fauci, Milley, and January 6th committee members ahead of potential future charges
President pardon - Read more

THE GOOD
Product Launches

Immuneel Therapeutics launches Qartemi, India’s first home-grown CAR-T cell therapy for adult B-cell non-Hodgkin lymphoma
Cell therapy, lymphoma, cancer, CAR-T - Read more

THE GOOD
Research

Large study reveals GLP-1 drugs may help with addiction, dementia and mental health, while at the same time highlighting potential risks
GLP-1, addition, dementia, mental health - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech🧬🦠🔬

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉 

THE UGLY
No Bad News Today!

(Though we have one ugly story 👇)

THE UGLY
Public Health

President Trump signs executive order withdrawing US support from WHO, citing COVID-19 mishandling, reforms failure, and unfair payment structure compared to other nations
World Health Organization, public health, pandemic preparedness - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here